SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Bayer AG BAYRY OTC

Other OTC • Healthcare • Drug Manufacturers - General • DE • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Bayer AG (BAYRY) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $11.90. It has a SharesGrow Score of 32/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Financials: revenue is $43.8B, -4.8%/yr average growth. Net income is $3.5B (loss), growing at -64.6%/yr. Net profit margin is -7.9% (negative). Gross margin is 59.2% (-1.6 pp trend).

Balance sheet: total debt is $37.4B against $25.9B equity (Debt-to-Equity (D/E) ratio 1.44, moderate). Current ratio is 1 (adequate). Debt-to-assets is 33.9%. Total assets: $110.6B.

Analyst outlook: 1 / 3 analysts rate BAYRY as buy (33%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 25/100 (Fail), Health 50/100 (Partial), Moat 80/100 (Pass), Future 20/100 (Fail), Income 10/100 (Fail).

BAYRY SharesGrow Score Overview

33/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 25/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 80/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BAYRY

No analyst coverage available for this stock.

BAYRY: -4.8%/yr revenue is, -64.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

BAYRY: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet BAYRY: Debt-to-Equity (D/E) ratio 1.44 (moderate), Current ratio is 1 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

BAYRY: Gross margin is 59.2% (-1.6 pp trend), $47B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 80/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 3 analysts rate BAYRY as buy (33%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

BAYRY: Net profit margin is -7.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range5.3-14.85

Volume167.2K

Avg Volume (30D)1.55M

Market Cap$46.76B

Beta (1Y)0.89

Dividend Yield$0.0300

Share Statistics

EPS (TTM)-0.88

Shares Outstanding$3.93B

IPO Date1996-11-18

Employees90,587

CEOWilliam N. Anderson

Financial Highlights & Ratios

Revenue (TTM)$43.78B

Gross Profit$25.92B

EBITDA$10.57B

Net Income$-3.48B

Operating Income$6.68B

Total Cash$7.85B

Total Debt$37.43B

Net Debt$30.76B

Total Assets$110.56B

Price / Earnings (P/E)-13.5

Price / Sales (P/S)1.07

Analyst Forecast

Rating ConsensusHold

Analysts Covering3

Buy 33% Hold 67% Sell 0%

Company Info

CountryDE

ExchangeOther OTC

CurrencyUSD

ISINUS0727303028

Price Chart

BAYRY

Bayer AG ↗ · Other OTC

Healthcare • Drug Manufacturers - General

5.30 52WK RANGE 14.85

People Also View

Roche Holding AG

AstraZeneca PLC

Merck & Co., Inc.

Gilead Sciences, Inc.

Bristol-Myers Squibb Company

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message